Abstract
Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management. This analysis included 1088 patients who received ≥ 2 prior therapies, including lenalidomide and bortezomib, and progressed ≤ 60 days of last therapy. Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required. The most common grade 3/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and/or supportive care. Pomalidomide plus low-dose d...Continue Reading
References
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Dec 13, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Brian G M DurieUNKNOWN Scientific Advisors of the International Myeloma Foundation
Sep 23, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marcio Nucci, Elias Anaissie
Nov 13, 2009·Leukemia·H QuachH M Prince
Dec 24, 2011·Leukemia·P G RichardsonP Sonneveld
Jun 29, 2012·Seminars in Hematology·Andrzej Jakubowiak
Dec 18, 2012·Blood·Paul G RichardsonKenneth C Anderson
Jan 16, 2013·Blood·Xavier LeleuUNKNOWN Intergroupe Francophone du Myélome
Sep 7, 2013·The Lancet Oncology·Jesus San MiguelMeletios Dimopoulos
Jan 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboRobert Z Orlowski
Jan 15, 2014·Blood·Paul G RichardsonKenneth C Anderson
Feb 6, 2014·Leukemia·M A DimopoulosJ F S Miguel
Oct 1, 2014·Expert Review of Hematology·Guillemette FouquetXavier Leleu
Oct 26, 2014·Haematologica·Cecilie BlimarkSigurdur Y Kristinsson
Feb 1, 2015·Leukemia Research·G MeleN Di Renzo
Apr 4, 2015·Blood·Ajay K NookaSagar Lonial
Jul 28, 2015·American Journal of Hematology·Wilson I GonsalvesLuciano J Costa
Oct 4, 2015·Haematologica·Evangelos TerposUNKNOWN European Myeloma Network
Dec 30, 2015·Leukemia·J LaubachP G Richardson
Apr 16, 2016·Haematologica·Katja C WeiselJesus San Miguel
May 27, 2016·Blood·Meletios A DimopoulosPhilippe Moreau
Jun 9, 2016·Leukemia & Lymphoma·David S SiegelAntonio Palumbo
Jun 11, 2016·Future Oncology·Cyrille Touzeau, Philippe Moreau
Aug 2, 2016·Haematologica·Pieter Sonneveld, Annemiek Broijl
Aug 20, 2016·OncoTargets and Therapy·Nishitha ThumallapallyTerenig Terjanian
Citations
Mar 7, 2018·Current Treatment Options in Cardiovascular Medicine·Dae Hyun Lee, Michael G Fradley
Feb 3, 2018·European Journal of Haematology·Pauline GueneauMathieu Boulin
Nov 8, 2017·Drugs·Sheridan M Hoy
Nov 5, 2019·Expert Review of Anticancer Therapy·Evangelos Eleutherakis-PapaiakovouMeletios A Dimopoulos
Jan 27, 2019·Molecular and Clinical Oncology·Eiseki UsamiTomoaki Yoshimura
Nov 8, 2020·European Journal of Cancer Care·Amélie CransacMathieu Boulin
Dec 11, 2020·The Oncologist·Cissimol P JosephTracy Havnaer
Feb 11, 2021·Blood Cancer Journal·Jacob P LaubachPaul G Richardson
Mar 7, 2020·Best Practice & Research. Clinical Haematology·Kylee MaclachlanDickran Kazandjian
Jul 5, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Haisam AbidMuhammad Bilal Abid
Sep 24, 2019·JACC. CardioOncology·Ronald M Witteles, Michaela Liedtke